BiotechTube

Nivolumab + Cabozantinib

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoid Tumor

Conditions

Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors

Trial Timeline

Dec 26, 2019 → Jan 31, 2024

NCT ID
NCT04197310

About Nivolumab + Cabozantinib

Nivolumab + Cabozantinib is a phase 2 stage product being developed by Bristol Myers Squibb for Carcinoid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04197310. Target conditions include Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors.

What happened to similar drugs?

1 of 9 similar drugs in Carcinoid Tumor were approved

Approved (1) Terminated (1) Active (7)
✅lanreotide (Autogel formulation)IpsenApproved
🔄Pasireotide + OctreotideNovartisPhase 3
🔄Octreotide + Placebo + EverolimusNovartisPhase 3
❌lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
🔄Lanreotide + PlaceboIpsenPhase 3
🔄Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
🔄Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04197310Phase 2Completed
NCT03316586Phase 2Completed

Competing Products

20 competing products in Carcinoid Tumor

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Somatostatin AnalogEli LillyPhase 2
35
PasireotideNovartisPhase 1
29
Pasireotide + OctreotideNovartisPhase 3
40
Pasireotide (SOM230)NovartisPhase 2
35
Octreotide + Placebo + EverolimusNovartisPhase 3
40
LutatheraNovartisPhase 2
27
EPO906 epothilone BNovartisPhase 2
35
PanitumumabAmgenPhase 2
27
AxitinibPfizerPhase 2
35
Lanreotide + Placebo (for sunitinib) + SunitinibPfizerPhase 2
31
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatinSanofiPhase 2/3
30
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
29
lanreotide (Autogel formulation)IpsenApproved
40
Lanreotide + PlaceboIpsenPhase 3
37
BIM 23A760IpsenPhase 2
24
Randomized: 40 mg Paltusotine + Randomized: 80 mg PaltusotineCrinetics PharmaceuticalsPhase 2
32
Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
44
Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
34
Telotristat etiprateLexicon PharmaceuticalsPhase 3
34
500 mg [14C]-LX1606Lexicon PharmaceuticalsPhase 1
23